




Replexa+ Retrospective Patient Analysis - Neuropathy

ProMedTek has conducted a retrospective analysis of 1,836 Replexa+ patients ranging in use from 2018 through 2019. As an addendum to the Replexa+ Retrospective Patient Analysis white paper, ProMedTek has also produced summary findings on several key patient and department subgroups. This is the patient compliance and outcome summary for the 441 patients treated for Neuropathy.

NEUROPATHY COMPLIANCE

Of the 441 patients treated for Neuropathy, over 87% of patients were compliant to the Replexa+ treatment. These results are significantly higher than typically expected noncompliance rates (~50%) for prescribed treatments [1]. We attribute the higher rate of compliance to the ProMedTek Patient Support Program.



OUTCOME	N, %
Compliant Only	386, 87.53%
Noncompliant Only	55, 12.47%
SPECIFIC TREATMENT OUTCOMES	
Did not want to use	39, 70.91%
Unable to use due to extenuating circumstances	15, 27.27%
Did not see expected results	2, 3.64%

Outcomes for patients reported as noncompliant (N=55). Patients could report multiple reasons for noncompliance.

NEUROPATHY PRIMARY ENDPOINT


Of the 386 compliant patients, over 95% of patients reported a positive outcome, while fewer than 5% of patients were unresponsive.

OUTCOME	N, %
Positive	368, 95.34%
Unresponsive	18, 4.66%

Treatment response of patients reported after compliant use of Replexa+ (N=386).

NEUROPATHY SECONDARY ENDPOINT

In addition to a reduction in pain, several other specific treatment outcomes were assessed based on self-report after patients completed Replexa+ treatment. Of the patients reported having a reduction in pain, a notable proportion of patients also indicated an improvement in mobility, an increase in activity level, a reduction in numbness, or an improvement in sleep after Replexa+ treatment.



Specific treatment outcomes for patients who reported a positive outcome after discontinuation of Replexa+ (N=368). Patients could report multiple outcomes.

REFERENCES: [1] - Kleinsinger, F. (2018). The Unmet Challenge of Medication Nonadherence. The Permanente Journal. doi: 10.7812/tpp/18-033 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045499/>